ResMed Inc. Common Stock (RMD)
Stock · NYSE · Health Care
$239.08as of 10/16/2026
Price chart
Active signals
RMD Signal Track Record
How signals performed across all stocks →What RMD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| 200-Day Moving Average TouchActive now | 31 | -1.3% | 39% | October 7, 2026 |
| Volume Spike | 31 | +2.2% | 65% | September 18, 2026 |
| Bollinger Band Breakout | 24 | -0.8% | 46% | August 4, 2026 |
| Bollinger Band Breakdown | 21 | +3.1% | 52% | May 29, 2026 |
| Any 20-session window (baseline) | +0.1% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RMD
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, r…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 11,370
- Website
- www.resmed.com/
Fundamentals
- 1-day range
- $237.97$242.54
- Market cap
- $32.38B
- P/E (trailing)
- 22.23
- P/E (forward)
- 18.06
- EPS (trailing)
- $10.44
- Dividend yield
- 1.25%
- Beta
- 0.78
- Avg. volume
- 1.29M
- Ex-dividend date
- August 20, 2026
- Dividend pay date
- September 24, 2026
How ResMed Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Aug 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
17 analyst ratings
ResMed Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RMDResMed Inc. Common Stock$238.97▼ 1.35%Market cap $32.38BP/E 22.23$180.27$277.67
- DXCMDexCom Inc. Common Stock$86.04▼ 1.90%Market cap $31.33BP/E 32.73$54.11$92.59
- WSTWest Pharmaceutical Services Inc. Common Stock$384.02▲ 0.26%Market cap $24.53BP/E 48.71$223.83$386
- MDLNMedline Inc. Class A Common Stock$35.96▼ 1.67%Market cap $45.34BP/E 69.38$31.49$50.88
- BDXBecton Dickinson and Company Common Stock$191.75▼ 1.04%Market cap $48.79BP/E 54.13$127.59$193.07
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RMD ResMed Inc. Common Stock | $32.38B | 22.23 | $238.97 | ▼ 1.35% | $180.27$277.67 |
| DXCM DexCom Inc. Common Stock | $31.33B | 32.73 | $86.04 | ▼ 1.90% | $54.11$92.59 |
| WST West Pharmaceutical Services Inc. Common Stock | $24.53B | 48.71 | $384.02 | ▲ 0.26% | $223.83$386 |
| MDLN Medline Inc. Class A Common Stock | $45.34B | 69.38 | $35.96 | ▼ 1.67% | $31.49$50.88 |
| BDX Becton Dickinson and Company Common Stock | $48.79B | 54.13 | $191.75 | ▼ 1.04% | $127.59$193.07 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ResMed Q4 2026 Earnings Call Transcriptbenzinga · 10/12/2026
- Wednesday's session: top gainers and losers in the S&P500 indexChartMill · 10/7/2026
- Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%Benzinga · 10/7/2026
- ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality FundamentalsChartMill · 10/7/2026
- SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For October 2026SeekingAlpha · 10/6/2026
- ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings?Yahoo · 10/5/2026
- 2 Cash-Producing Stocks with Promising Prospects and 1 We Brush OffYahoo · 10/2/2026
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026Yahoo · 10/1/2026
- Top 25 High-Growth Dividend Stocks For October 2026SeekingAlpha · 10/1/2026
Insider Activity
Insider Actions →- Michael J. Farrell · October 7, 2026 · Option Exercise5.0K @ $146.34
- Michael J. Farrell · October 7, 2026 · Sale5.0K @ $226.33
- Michael J. Farrell · September 8, 2026 · Option Exercise5.0K @ $146.34
- Michael J. Farrell · September 8, 2026 · Sale5.0K @ $222.44
- Peter C. Farrell · September 2, 2026 · Sale970 @ $234.73
- Michael J. Rider · August 14, 2026 · Grant3.2K
- Justin Leong · August 14, 2026 · Grant6.5K
- Michael J. Farrell · August 14, 2026 · Grant13.5K
- Bloomer Aaron · August 14, 2026 · Grant9.1K
- Michael J. Farrell · August 7, 2026 · Option Exercise5.0K @ $146.34
- Michael J. Farrell · August 7, 2026 · Sale5.0K @ $205.69
- Peter C. Farrell · August 5, 2026 · Sale8.0K @ $225
- Michael J. Farrell · July 7, 2026 · Option Exercise5.0K @ $146.34
- Michael J. Farrell · July 7, 2026 · Sale5.0K @ $218.55
- Michael J. Farrell · June 8, 2026 · Option Exercise5.0K @ $146.34
Institutional Ownership
March 31, 2026
- Total shares held
- 88.10M
- Total value held
- $19.20B
- Institutional holders
- 931
- Unknown12.09M
- Unknown9.47M
- Unknown6.64M
- Unknown4.93M
- Unknown4.35M
- Unknown2.69M
- Unknown1.96M
- Unknown1.73M
- Unknown1.54M
- Unknown1.42M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released
ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.